


PHARMACEUTICAL 2022

Equillium Inc. Rank 281 of 475





PHARMACEUTICAL 2022

Equillium Inc. Rank 281 of 475

The relative strengths and weaknesses of Equillium Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Equillium Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 140% points. The greatest weakness of Equillium Inc. is the variable Net Income, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -163%, being 113% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	83,370
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,915
Liabilities, Non-Current	1,235
Other Assets	1,798
Other Compr. Net Income	159
Other Expenses	0
Other Liabilities	8,750
Other Net Income	-1,266
Property and Equipment	237
Research and Development	26,379
Revenues	0
Selling, General and Administrative Expense	11,407

Output Variable	Value in 1000 USD
Assets	85,405
Liabilities	18,900
Expenses	37,786
Stockholders Equity	66,505
Net Income	-39,052
Comprehensive Net Income	-38,972
Economic Capital Ratio	-163%